Sign inJoin waitlistJoin the waitlist

CL

Curtis Lachowiez

Assistant Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine · Oregon Health & Science University

Credentials: · · · · · ·

History

Oregon Health & Science University
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2019–2022
Internal Medicine
Oregon Health & Science University
2015–2018
University of Nebraska Medical Center
2011–2015

Research

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Journal of Clinical Oncology · 2021 · 294 citations
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
Blood Advances · 2020 · First of 23 authors · 150 citations
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Blood Cancer Discovery · 2023 · First of 27 authors · 119 citations

Courtney DiNardo
21 papers
Sanam Loghavi
17 papers
Naval Daver
13 papers
Koichi Takahashi
12 papers
Tapan Kadia
12 papers
Hagop Kantarjian
11 papers
GB
Gautam Borthakur
10 papers
Guillermo Garcia-Manero
10 papers
Marina Konopleva
10 papers
Nicholas Short
10 papers
RS
Ronan Swords
10 papers
Naveen Pemmaraju
9 papers

Clinical trials

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 2
OHSU Knight Cancer Institute
2025–2029
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Principal investigator · Recruiting · Phase 2
OHSU Knight Cancer Institute
2025–2028
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Principal investigator · Recruiting · Phase 1
OHSU Knight Cancer Institute
2024–2028
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Site PI · Recruiting · Phase 1
SystImmune Inc.
2024–2027